Literature DB >> 2448729

Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis.

Henning Vaerøy1, Robert Helle, Øystein Førre, Erik Kåss, Lars Terenius.   

Abstract

In 30 patients with diagnosed fibromyalgia, the CSF level of immunoreactive substance P (SP) was investigated. Compared to normal values (9.6 +/- 3.2 fmol/ml), all the patients had elevated CSF levels of SP (36.1 +/- 2.7 fmol/ml, range 16.5-79.1 fmol/ml). Anamnestic information from the patients revealed that 53.3% had Raynaud/Raynaud-like phenomenon localized in the fingers, the toes or both. Although SP levels did not differ significantly in patients with or without the Raynaud phenomenon, elevated activity may be present in the peripheral branches of SP neurons which could be responsible for the last (rubor) phase of the triphasic Raynaud's phenomenon. SP levels were significantly higher in patients who were smokers (40.1 +/- 2.7 fmol/ml, range 25.3-64.1 fmol/ml), compared to patients who were non-smokers (29.2 +/- 5.0 fmol/ml, range 16.5-79.1 fmol/ml). We propose elevated CSF levels of SP and the Raynaud phenomenon as characteristic features for fibromyalgia with potential as diagnostic markers of the disease and further that smoking might be an aggravating factor for its pathogenesis or development.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2448729     DOI: 10.1016/0304-3959(88)90019-X

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  80 in total

Review 1.  Sympathetic nervous system function in fibromyalgia.

Authors:  F Petzke; D J Clauw
Journal:  Curr Rheumatol Rep       Date:  2000-04       Impact factor: 4.592

Review 2.  Neuropharmacologic targets and agents in fibromyalgia.

Authors:  Rie Suzuki; Anthony H Dickenson
Journal:  Curr Pain Headache Rep       Date:  2002-08

Review 3.  Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide.

Authors:  Salih Ozgocmen; Huseyin Ozyurt; Sadik Sogut; Omer Akyol
Journal:  Rheumatol Int       Date:  2005-11-20       Impact factor: 2.631

Review 4.  Review of overlap between thermoregulation and pain modulation in fibromyalgia.

Authors:  Alice A Larson; José V Pardo; Jeffrey D Pasley
Journal:  Clin J Pain       Date:  2014-06       Impact factor: 3.442

5.  The NK1 receptor mediates both the hyperalgesia and the resistance to morphine in mice lacking noradrenaline.

Authors:  Luc Jasmin; Duc Tien; David Weinshenker; Richard D Palmiter; Paul G Green; Gabriella Janni; Peter T Ohara
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

6.  Clinical evidence for cervical myelopathy due to Chiari malformation and spinal stenosis in a non-randomized group of patients with the diagnosis of fibromyalgia.

Authors:  Dan S Heffez; Ruth E Ross; Yvonne Shade-Zeldow; Konstantinos Kostas; Sagar Shah; Robert Gottschalk; Dean A Elias; Alan Shepard; Sue E Leurgans; Charity G Moore
Journal:  Eur Spine J       Date:  2004-04-09       Impact factor: 3.134

Review 7.  Evidence of involvement of central neural mechanisms in generating fibromyalgia pain.

Authors:  Roland Staud
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

8.  [Fibromyalgia: behavioral medicine interventions].

Authors:  F Petermann; M C Holtz; B van der Meer; B Krohn-Grimberghe
Journal:  Schmerz       Date:  2007-10       Impact factor: 1.107

Review 9.  Neurogenic inflammation in fibromyalgia.

Authors:  Geoffrey Littlejohn; Emma Guymer
Journal:  Semin Immunopathol       Date:  2018-03-19       Impact factor: 9.623

10.  Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp) versus placebo.

Authors:  H Vaerøy; A Abrahamsen; O Førre; E Kåss
Journal:  Clin Rheumatol       Date:  1989-06       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.